Coherus Biosciences | CHRS - Cash And Equivalent


Coherus Biosciences reported $82.92M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amarin USD 156.51M 12.95M Sep/2026
Amgen USD 13.19B 799M Sep/2026
Baxter International USD 1.98B 175M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Fujifilm JPY 170.55B 9.68B Mar/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
Ironwood Pharmaceuticals USD 86.38M 7.25M Sep/2026
Merck USD 9.55B 2.7B Sep/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Pacira USD 1.79B 1.58B Sep/2026
Perrigo USD 436.6M 36.9M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
Teva Pharmaceutical Industries USD 4.08B 430M Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026
Xencor USD 59.62M 14.96M Sep/2026
Zoetis USD 1.33B 143M Sep/2026